Abstract
Valproic acid (VPA) is an effective anticonvulsant useful in many types of epilepsy and, although it is usually well tolerated, it has been associated with many neurological and systemic side effects. Among these, one of the most important is VPA-induced hyperammonemic encephalopathy (VHE): its typical signs are acute onset of impaired consciousness, focal neurologic symptoms, and increased seizure frequency. The pathogenesis of VHE is still unclear, but it has been suggested that hyperammonemia can produce encephalopathy via inhibition of glutamate uptake by astrocytes which may lead to potential neuronal injury and perhaps cerebral edema. Glutamine production is increased, whereas its release is inhibited in astrocytes exposed to ammonia. The elevated glutamine increases intracellular osmolarity, promoting an influx of water with resultant astrocytic swelling. This swelling could compromise astrocyte energy metabolism and result in cerebral edema with increased intracranial pressure. Moreover, VHE seems to be more frequently in patients with carnitine deficiency or with congenital urea cycle enzymatic defects.
Similar content being viewed by others
REFERENCES
Appleton, R.E., Farrel, K., and Applegarth, D.A. (1990). The high incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects. Can. J. Neurol. Sci. 17:145-148.
Bicknese, A.R., May, W., and Hickey, W.F. (1992). Early childhood hepatocerebral degeneration misdiagnosed as valproate hepatotoxicity. Ann. Neurol. 32:767-775.
Blindauer, K.A., Harrington, G., Morris, G.L., III, and Ho, K. C. (1998). Fulminant progression of demyelinating disease after valproate-induced encephalopathy. Neurology 51:292-295.
Bryant, A.E., and Dreifuss, F.E. (1996). Valproic acid hepatic fatalities. III: U.S. experience since 1986. Neurology 46:465-469.
Chapoy, P.R., Angelini, C., Brown, W.J., Stiff, J.E., Shug, A.L., and Cederbaum, S.D. (1980). Systemic carnitine deficiency-A treatable inherited lipid-storage disease presenting as Reye's syndrome. N. Engl. J. Med. 303:1389-1394.
Chayasirisobbon, S., and Russel, M. (1983). Valproic acid and intractable seizures in severely brain-damaged patients. Neurology 33:99-101.
Coulter, D.L., and Allen, R.J. (1980). Secondary hyperammonemia. A possible mechanism for valproate encephalopathy. Lancet i:1310-1311.
Coulter, D.L., Allen, R.J., and Arbor, A. (1981). Hyperammonemia with valproic acid therapy. J. Pediatr. 99:317-319.
Dodson, W.E., and Tasch, V. (1981). Pharmacology of valproic acid in children with severe epilepsy: Clearance and hepatotoxicity. Neurology 31:1047-1050.
Dreifuss, F.E. (1983). Lennox-Gastaut syndrome. In: Dreifuss, F.E. (ed.), Pediatric Epileptology. Classification and Management of Seizures in the Child, Wright, Boston, MA.
Duarte, J., Macias, S., Coria, F., Fernandez, E., and Clavaria, L.E. (1993). Valproate-induced coma: Case report and literature review. Ann. Pharmacother. 27:582-583.
Fraser, C.M., Sills, G.J., Forrest, G., Thompson, G.G., and Brodie, M.J. (1999). Effects of antiepileptic drugs on glutamine synthetase activity in mouse brain. Br. J. Pharmacol. 126:1634-1638.
Gago, M.C., Novo, I., and Segade, S.R. (1990). Effects of valproic acid on the urea cycle and carnitine metabolism. Int. Pediatr. 5:54-56.
Gidal, B.E., Inglese, C.M., Meyer, J.F., Pitterle, M.E., Antonopoulos, J., and Rust, R.S. (1997). Diet-and valproate-induced transient hyperammonemia: Effect of L-carnitine. Pediatr. Neurol. 16:301-305.
Haidukewych, D., John, G., Zielinski, J.J., and Rodin, E.A. (1985). Chronic valproic acid therapy and incidence of increases in venous plasma ammonia. Ther. Drug Monit. 7:290-294.
Hamer, H.M., Knake, S., Schomburg, U., and Rosenow, F. (2000). Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 54:230-232.
Honeycutt, D., Callahan, K., Rutledge, L., and Evans, B. (1992). Heterozygote ornithine transcarbamylase deficiency presenting as symptomatic hyperammonemia during initiation of valproate therapy. Neurology 42:666-668.
Kay, J.D., Hilton-Jones, D., and Hyman, N. (1986). Valproate toxicity and ornithine carbamoyltransferase deficiency. Lancet ii:1283-1284.
Kifune, A., Kubota, F., Shibata, N., Akata, T., and Kikuchi, S. (2000). Valproic acid-induced hyperammonemic encephalopathy with triphasic waves. Epilepsia 41:909-912.
Koch, K.M., Wilensky, A.J., and Levy, R. H. (1989). Beta-oxidation of valproic acid. Effects of fasting and glucose in humans. Epilepsia 30:782-789.
Laub, M.C. (1986). Nutritional influence on serum ammonia in young patients receiving sodium valproate. Epilepsia 27:55-59.
Leao, M. (1995). Valproate as a cause of hyperammonemia in heterozygotes with ornithine-transcarbamylase deficiency. Neurology 45:593-594.
Lenn, N.J., Ellis, W.G., and Washburn, E.R. (1990). Fatal hepatocerebral syndrome in siblings discordant for exposure to valproate. Epilepsia 31:578-583.
Marescaux, C., Warter, J.M., Micheletti, G., Rumbach, L., Coquillat, G., and Kurtz, D. (1982). Stuporous episodes during treatment with sodium valproate: Report of seven cases. Epilepsia 23:297-305.
Marescaux, C., Warter, J.M., Laroye, M., Rumbach, L., Micheletti, G., Koehl, C., et al. (1983). Le valproate de sodium: une drogue Hyperammniémiante. Etude chez l'épileptique et chez le volontaire sain. J. Neurol. Sci. 58:195-198.
Marini, A.M., Zaret, B.S., and Beckner, R.R. (1988). Hepatic and renal contributions to valproate-induced hyperammonemia. Neurology 38:365-371.
Matsuda, I., Ohtani, Y., and Ninomiya, N. (1986). Renal handling of carnitine in children with carnitine deficiency and hyperammonemia associated with valproate therapy. J. Pediatr. 109:131-133.
Murphy, J.V., and Marquardt, K. (1982). Asymptomatic hyperammonemia in patients receiving valproic acid. Arch. Neurol. 39:591-593.
Noremberg, M.D. (1996). Astrocytic-ammonia interactions in hepatic encephalopathy. Semin. Liver Dis. 16:245-253.
Oechsner, M., Steen, C., Sturenburg, H.J., and Kohlschutter, A. (1998). Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognised ornithine transcarbamylase deficiency. J. Neurol. Neurosurg. Psychiatry 64:680-682.
Ohtani, Y., Endo, F., and Matsuda, I. (1982). Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J. Pediatr. 101:782-785.
Porter, R.J. (1984). Therapy: General considerations. In: Walton, J.N. (ed.), Major Problems in Neurology. Vol. 12: Epilepsy: 100 Elementary Principles, Saunders, London, p. 69.
Ratnaike, R.N., Schapel, G.J., Purdie, G., Rischbieth, R.H.C., and Hoffmann, S. (1986). Hyperammonemia and hepatotoxicity during chronic valproate therapy: Enhancement by combination with other antiepileptic drugs. Br. J. Clin. Pharmacol. 22:100-103.
Rumbach, L., Cremel, G., and Marescaux, C. (1989). Valproate-induced hyperammonemia of renal origin: Effects of valproate on gluatmine transport in rat kidney mitochondria. Biochem. Pharmacol. 38:3963-3967.
Sackellares, J.C., Lee, S.I., and Dreifuss, F.E. (1979). Stupor following administration of valproic acid to patients receiving other antiepileptic drugs. Epilepsia 20:697-703.
Sakemi, K., and Takada, G. (1998). Effect of carnitine on valproic acid concentrations in serum, brain, and liver. Pediatr. Neurol. 18:331-333.
Sakir, A., Vildan, B., Mehdi, T., Ozlem, H., Refik, B., and Levent, K. (1997). Asymptomatic hyperammonemia in children treated with valproic acid. J. Child Neurol. 12:461-463.
Sato, S., White, B.G., and Penry, J.K. (1982). Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 2:157-159.
Sherard, E.S., Steinman, G.S., and Couri, D. (1980). Treatment of childhood epilepsy with valproic acid: Result of the first 100 patients in a 6-month trial. Neurology 30:31-35.
Sills, J.A., Trefor-Jones, R.H., and Taylor, W.H. (1980). Valproate, hyperammonemia and hyperglycinemia. Lancet ii:260-261.
Stephens, J.R., and Levy, R.H. (1994). Effects of valproate and citrulline on ammonium-induced encephalopathy. Epilepsia 35:164-171.
Thom, H., Carter, P.E., Cole, G.F., and Stevenson, K.L. (1991). Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs. Dev. Med. Child Neurol. 33:795-799.
Verrotti, A., Greco, R., Morgese, G., and Chiarelli, F. (1999). Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs. Int. J. Clin. Lab. Res. 29:36-40.
Warter, J.M., Marescaux, C., Rumbach, L., Galmiche, J., Micheletti, G., Koehl, C., et al. (1981). L'hyperammoniémie isolée: une consequence fréquente des traitements par la valproate de sodium. Nouv. Presse Med. 10:3406-3409.
Warter, J.M., Marescaux, C., Chabrier, G., Rumbach, L., Micheletti, G., Reitzer, B., et al. (1984). Increase of valproate-induced hyperammonemia in normal subjects by carbohydrate intake. Neurology 34:1487-1490.
Williams, C.A., Tiefenbach, S., and McReynolds, J.W. (1984). Valproic acid-induced hyperammonemia in mentally retarded adults. Neurology 34:550-553.
Wyllie, E., Wyllie, R., Rothner, A.D., Erenberg, G., and Cruse, R.P. (1983). Valproate-induced hyperammonemia in asymptomatic children. Cleve. Clin. Q. 50:275-278.
Zaccara, G., Campostrini, R., Paganini, M., Messori, A., Valenza, T., Arnetoli, G., et al. (1984). Acute changes of blood ammonia may predict short-term adverse effects of valproic acid. Neurology 34:1519-1521.
Zaccara, G., Campostrini, R., Paganini, M., Messori, A., Valenza, T., Arnetoli, G., et al. (1987). Long-term treatment with sodium valproate: Monitoring of venous ammonia concentrations and adverse effects. Ther. Drug Monit. 9:34-37.
Zaret, B.S., Beckner, R. R., Marini, A. M., Wagle, W., and Passarelli, C. (1982). Valproate-induced hyperammonemia without clinical hepatic dysfunction. Neurology 32:206-209.
Rights and permissions
About this article
Cite this article
Verrotti, A., Trotta, D., Morgese, G. et al. Valproate-Induced Hyperammonemic Encephalopathy. Metab Brain Dis 17, 367–373 (2002). https://doi.org/10.1023/A:1021918104127
Issue Date:
DOI: https://doi.org/10.1023/A:1021918104127